Mesenchymal stem cells and cancer-associated fibroblasts as a therapeutic strategy for breast cancer.

BORZONE FR.; GIORELLO MB.; SANMARTIN MC.; YANNARELLI G.; MARTINEZ LM.; CHASSEING NORMA ALEJANDRA

BRITISH JOURNAL OF PHARMACOLOGY

WILEY-BLACKWELL PUBLISHING, INC

Lugar: Londres; Año: 2022

0007-1188

El trabajo fue aprobado en el 2022 (Epub 2022 May 17), en British Journal of Pharmacology y salio en Pubmed como Br J Pharmacology 2022, 11–19; DOI: 10.1111/bph.1586, cuyo PDF se informa. En esta oportunidad fuimos invitados por los Editores. Sin embargo, luego aparece en el 2024 como: British Journal of Pharmacology 181(2): 238-256, 2024. DOI: 10.1111/bph.15861. ABSTRACT:Breast cancer is the most common type of cancer and the leading cause of deathamong women. Recent evidence suggests that mesenchymal stromal/stem cells andcancer-associated fibroblasts (CAFs) have an essential role in cancer progression,invasion and therapy resistance. Therefore, they are considered as highly promisingfuture therapeutic targets against breast cancer. The intrinsic tumour tropism andimmunomodulatory capacities of mesenchymal stromal/stem cells are of special relevancefor developing mesenchymal stromal/stem cells-based anti-tumour therapiesthat suppress primary tumour growth and metastasis. In addition, the utilization oftherapies that target the stromal components of the tumour microenvironment incombination with standard drugs is an innovative tool that could improve patients response to therapies and their survival. In this review, we discuss the currently availableinformation regarding the possible use of mesenchymal stromal/stem cellsderivedanti-tumour therapies, as well as the utilization of therapies that target CAFsin breast cancer microenvironment. Finally, these data can serve as a guide map forfuture research in this field, ultimately aiding the effective transition of these resultsinto the clinic. KEYWORDS: breast cancer, cancer-associated fibroblasts, mesenchymal stem cells, therapeutic approaches.